PPHN (persistent pulmonary hypertension of the newborn)
PPHN, or persistent pulmonary hypertension of the newborn, is when the blood vessels in the lungs of a newborn stay narrow after birth instead of opening up, so blood bypasses the lungs and the baby gets too little oxygen. It is rare and serious. US labels for SSRIs say exposure late in pregnancy may raise the risk. Even so, the risk stays small, at around 3 in 1,000 babies compared with 1 to 2 in 1,000 in general. If you are pregnant or planning a pregnancy, do not stop an antidepressant suddenly; talk to your doctor, as untreated depression also carries risks.
Also called: Persistent pulmonary hypertension of the newborn, SSRIs and PPHN.
Written by Alena Kozlova, PhD, from published studies and prescribing information.
Definition medically reviewed by Dr. Jason Tan, Consultant Psychiatrist, on November 11, 2026, this definition only. Next review: November 11, 2027.
What is PPHN?
Before birth the lung vessels of a baby are narrow and most blood goes around the lungs, which the baby does not breathe with yet. The first breaths are meant to open those vessels up. In PPHN they stay narrow, blood keeps going past the lungs, and the baby is left short of oxygen. That is the persistent part of the name: the circulation the baby had before birth carries on afterwards. A 2025 review in Biomedicines describes PPHN as a disrupted move from fetal to newborn circulation, with high pressure in the lung vessels, blood shunted from right to left, and low oxygen that is hard to correct.
It is uncommon. The US prescribing information for Lexapro puts PPHN at 1 to 2 per 1,000 live births in the general population, which is 10 to 20 per 10,000, and says it carries substantial newborn illness and death. The Zoloft label groups PPHN with neonatal complications that can mean a longer hospital stay, breathing support and tube feeding.
What do US labels say about SSRIs and PPHN?
The Lexapro prescribing information says exposure to SSRIs, particularly later in pregnancy, may increase the risk for PPHN. The Zoloft label asks prescribers to monitor newborns exposed in the third trimester for PPHN and for drug discontinuation syndrome, so a team that knows what you take can watch for it.
The Zoloft label then describes one retrospective case-control study of 377 women whose babies were born with PPHN and 836 whose babies were born healthy, where the risk was about six times higher in babies exposed to an SSRI after the 20th week of pregnancy than in babies not exposed to an antidepressant. The same paragraph of the label gives a Swedish study of 831,324 births with a risk ratio of 2.4, so the two estimates printed side by side already differ.
How big is the risk?
PPHN is rare on every estimate, and the gap between exposed and unexposed babies is small. A 2015 study in JAMA used US Medicaid records for 3,789,330 pregnancies and compared antidepressant use late in pregnancy against no use. PPHN occurred in 31.5 per 10,000 babies exposed to an SSRI and in 20.8 per 10,000 babies not exposed to an antidepressant.
Among women with depression, and after the authors accounted for other differences between the groups, the gap shrank to an odds ratio of 1.10, with a range from 0.94 to 1.29. Counting only babies whose PPHN had no other cause, it was 1.28, with a range from 1.01 to 1.64. The authors wrote that their findings may be consistent with a possible increased risk, that the absolute risk was small, and that the increase looks more modest than earlier studies suggested.
Estimates still disagree. A 2019 meta-analysis of 11 studies found the odds about twice as high after exposure past the 20th week, around 29 cases per 10,000 babies who were exposed. UK guidance from UKTIS gives about 1 in 300 babies whose mother takes an SSRI, which is about 33 per 10,000. A small increase in risk is not ruled out, and on all of these numbers PPHN stays rare.
What happens if a baby does get PPHN?
PPHN is treated in a newborn intensive care unit, and the 2025 Biomedicines review sets out the steps. Doctors start with breathing support and surfactant to open the lungs, add medicines that widen the lung vessels, inhaled nitric oxide first among them, and in severe cases use ECMO, a machine that takes over the work of the lungs and heart. That is the reason the Zoloft label asks for newborns exposed in the third trimester to be monitored: a baby who is watched from the first hours gets this care early.
Who decides about an SSRI in pregnancy?
You do, together with your prescriber and your obstetric team. The US labels put the other side of the choice in plain words. The Zoloft label asks prescribers to consider the risks of untreated depression when stopping or changing an antidepressant during pregnancy and after birth. The Lexapro label says there are risks associated with untreated depression in pregnancy, and that women who stop antidepressants are more likely to have a relapse of major depression than women who stay on them. A relapse during pregnancy or in the weeks after birth is what sits on that side of the scales.
UKTIS asks you not to stop your medication without speaking to your GP or specialist first, and says that stopping an SSRI might affect your mental health and can also cause withdrawal symptoms. The same leaflet says it is very important that mental health conditions are properly treated during pregnancy and while caring for your baby. So both sides of the choice carry something, and it is a conversation to have early rather than a decision to make alone in the third trimester.
What to do
If you are pregnant or planning a pregnancy, tell your prescriber and your obstetric team which antidepressant you take and at what dose, and ask what they will watch for in your baby after birth. If your mood drops, say so at the next appointment rather than waiting for it to pass. If you have thoughts of harming yourself, call or text 988 in the US, or your local emergency number.
Find support near you
How withClaro helps
- Keep your doses and mood in one record
- Share a PDF report with your care team
Get the withClaro app on the App Store
Related terms
Sources
- U.S. Food and Drug Administration. Lexapro (escitalopram) tablets and oral solution: prescribing information. FDA / DailyMed, 2026.
- U.S. Food and Drug Administration. Zoloft (sertraline) tablets and oral solution: prescribing information. FDA / DailyMed, 2025.
- Huybrechts KF, Bateman BT, Palmsten K, Desai RJ, Patorno E, Gopalakrishnan C, Levin R, Mogun H, Hernandez-Diaz S. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA, 2015.
- Masarwa R, Bar-Oz B, Gorelik E, Reif S, Perlman A, Matok I. Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysis. American Journal of Obstetrics and Gynecology, 2019.
- Chojnacka K, Singh Y, Gahlaut S, Blaz W, Jerzak A, Szczapa T. Persistent Pulmonary Hypertension of the Newborn: A Pragmatic Review of Pathophysiology, Diagnosis, and Advances in Management. Biomedicines, 2025.
- UK Teratology Information Service (UKTIS). Escitalopram in pregnancy. Best Use of Medicines in Pregnancy (bumps), 2026.
All glossary terms